Equal Access to Therapeutics Act
United States117th CongressHR-6625House of Representatives
Updated: Feb 8, 2022
Summary
Equal Access to Therapeutics Act This bill prohibits using race or ethnicity as a factor in decisions about an individual's access to COVID-19 treatments (e.g., monoclonal antibody therapies). Specifically, the Department of Health and Human Services (HHS) may not adopt any policy or guidance that allows race or ethnicity to be factored into such decisions. Furthermore, the Secretary of HHS shall be personally liable for the death of any individual who is denied access to COVID-19 treatments pursuant to a prohibited policy or guidance. The bill also prohibits hospitals or other health care providers that have policies restricting access to COVID-19 treatments based on race or ethnicity from receiving federal funds.
Bill texts
All available records shown.
Timeline
Referred to the House Committee on Energy and Commerce.
House of Representatives
Introduced in House
Referred to the Subcommittee on Health.
House of Representatives
All available records shown.